For the DoxyPEP protocol itself — dosing, timing, the dairy rule, the esophagus risk, sun sensitivity, and the decision matrix for when to use it — read DoxyPEP: The Morning After Pill for Bacteria first. This guide covers the US-specific picture: the CDC's position, how to access it, and what it costs.

📊 The Evidence

The landmark DoxyPEP studies showed compelling results for MSM and transgender women:

  • 87% reduction in syphilis cases
  • 88% reduction in chlamydia cases
  • 55% reduction in gonorrhea cases

In 2023, the US CDC formally endorsed DoxyPEP as official federal guidance for gay and bisexual men and transgender women who have had a bacterial STI in the past year or who are at high behavioural risk.

🏛️ The CDC's Position

The CDC's endorsement reflects a specific public health calculation: syphilis rates in MSM communities were climbing 50%+ year-over-year in many US cities, and targeted post-exposure antibiotic use in high-risk individuals offered a meaningful way to reduce transmission without waiting for behavioural change alone. The resistance risk from targeted use in a defined population was judged less urgent than the harm from unchecked bacterial STI spread.

The practical result of CDC backing: you can walk into most LGBTQ+ health centers and ask for DoxyPEP, and most will prescribe it without needing to argue the case.

🎯 Who Should Consider It

The CDC's guidance targets:

  • MSM or transgender women who have been diagnosed with gonorrhoea, chlamydia, or syphilis in the past 12 months
  • MSM or transgender women who assess themselves at high risk based on sexual behaviour and the number of partners

If you're already on PrEP and testing every three months, you're exactly the population this is designed for. DoxyPEP sits alongside PrEP — it doesn't replace it, and it doesn't replace regular testing.

🏥 Where to Get It in the United States

LGBTQ+ health centers: The most straightforward route. Most experienced LGBTQ+ health centers have incorporated DoxyPEP into their standard PrEP clinic protocols since 2023–2024. Callen-Lorde, Fenway Health, Howard Brown, Los Angeles LGBT Center, Whitman-Walker, and similar centres are prescribing routinely.

Sexual health clinics: Most public health department sexual health clinics in major cities now offer DoxyPEP. Availability in smaller cities and rural areas is less consistent.

Telehealth: Services including MISTR, Folx Health, and Planned Parenthood Direct can prescribe DoxyPEP in most states alongside PrEP. This is the fastest route if you're not near an LGBTQ+ health center.

Primary care GP: Hit and miss. Some GPs are up to date with the CDC guidance; others aren't aware of DoxyPEP or are reluctant to prescribe it. Having the CDC guidance document on hand helps. The general section has guidance on navigating reluctant providers — see Finding an LGBTQ+-Affirming Doctor.

💵 Cost

Doxycycline is cheap and off-patent. A 10-tablet supply (five doses, as each dose is 200mg = two 100mg tablets) costs:

  • With insurance: $0–$10 typically — doxycycline is on virtually every generic formulary
  • GoodRx without insurance: $10–$30 for a supply sufficient for several months of use
  • Without insurance or GoodRx: ~$20–40 at most pharmacies

This is one of the most accessible medications in US sexual health. Cost is rarely the barrier.

⚠️ What DoxyPEP Does NOT Do

  • Does NOT prevent HIV — that's PrEP's function.
  • Does NOT protect against HPV or Hepatitis — vaccines cover those.
  • Does NOT replace regular testing — quarterly three-site testing is still required. DoxyPEP may actually reduce the yield of tests over time (fewer infections to find), but you still need to test.
  • Does NOT prevent future infections — it only reduces risk after a specific exposure.

🔬 The Resistance Question

The antibiotic resistance concern is real, not dismissible. Doxycycline resistance in gonorrhea is already observed in some settings. Responsible DoxyPEP use means:

  • Targeting it to genuinely high-risk situations, not using it after every sexual encounter as a routine
  • Continuing quarterly testing — this is how emerging resistance is caught
  • Discussing with your provider whether your risk profile justifies ongoing use

The CDC guidance is population-level; your individual decision should account for your specific risk level.

Related: